AntriaBio antriabio.com

AntriaBio offers the diabetes product candidate, AB101, a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia. In February 2013, Fits My Style merged with AntriaBio. Due to the merger, AntriaBio is now listed and trading on the OTC Bulletin Board and the OTCQB under the symbol "FMYY."

AntriaBio offers the diabetes product candidate, AB101, a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who requ...Show all

See All Exits Recent Exits

Phone: 650-241-9330

Fax:

890 Santa Cruz Ave

Menlo Park, 94025
California, United States

AntriaBio - Investments & Acquisitions

Show Real Data AntriaBio Investments
See all Recent Investments
Date Company Round Amount Co-investors
2013-01-07PR PharmaceuticalsAsset Sale
See all 1 investments